On Thursday, Bluebird Bio Inc. (NASDAQ:BLUE) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a ...

As novel gene therapies emerge, there is a complex interplay among their potential benefits, the burdens they may impose and ...

The FDA has accepted for review the resubmitted BLA for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa.

Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a ...

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...

Friday Headlines: 38 y/o Brent Maloy is the first person in SC to undergo gene therapy treatment after living with Hemophilia ...

Understanding what to patent versus what to keep as a trade secret is an increasingly important and challenging decision ...

Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...

A biohacker who is 'reverse aging' has revealed the horrifying side-effect of a procedure to make him look younger.

StitchR makes it possible to deliver larger payloads with current vectors, expanding the list of diseases targetable by gene therapies.

High cost is a major challenge. The global cell and gene therapy market is projected to expand by $6.56b, reflecting an ...